Gail J. Roboz, Ellen K. Ritchie, Tania Curcio, Juliette Provenzano, Rebecca Carlin, Michael Samuel, Beth Wittenberg, Madhu Mazumdar, Paul J. Christos, Susan Mathew, Sandra Allen-Bard and Eric J. Feldman Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia Cancer 113
Version of Record online: 29 SEP 2008 | DOI: 10.1002/cncr.23855
The authors hypothesized that arsenic trioxide may augment the clinical activity of low-dose cytarabine in older patients with acute myeloid leukemia (AML), and they conducted a phase 1/2 study to determine the safety and efficacy of the combination. The results indicated that arsenic trioxide combined with low-dose cytarabine appeared to improve responses in elderly patients who had AML compared with either agent alone.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field